---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-101624"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:27:07.962951+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axsome Q2 product revenue $150M (+72% YoY); AUVELITY sales $119.6M

## Summary
- Total net product revenue $150.0M, up 72% YoY and 24% sequentially.
- AUVELITY net sales $119.6M (+84% YoY); ~192k prescriptions written in Q2.
- Net loss narrowed to $48.0M ($0.97/share) from $79.3M ($1.67/share) in Q2 2024.
- Cash $303.0M; management says sufficient to fund operations into cash flow positivity.
- Pipeline: sNDA for AXS-05 in Alzheimer's agitation on track for Q3 2025; NDA for AXS-12 in narcolepsy expected Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-101624
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/0000950170-25-101624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-101624
- JSON: https://secwatch.observer/filing/0000950170-25-101624.json
- Plain text: https://secwatch.observer/filing/0000950170-25-101624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.